Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04605679 · ClinicalTrials.gov registry record · NA

Hepatitis C Virus (HCV) Positive Kidney Grafts in HCV Negative Recipients

A NA study of Kidney Failure, sponsored by Loma Linda University.

Active
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT04605679 is a NA study of Kidney Failure that is active but no longer recruiting, run by Loma Linda University. The registered enrollment target is 31 participants, below the 586-participant average among 18 other Kidney Failure trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04605679, a NA study of Kidney Failure, is active but no longer recruiting, sponsored by Loma Linda University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

To determine the efficacy and safety of transplanting HCV positive kidney allografts to HCV sero-negative patients who are on the waiting list.

Conditions Studied

Interventions

  • PROCEDURE Kidney Transplantation

Study Locations (1)

California

  • Loma Linda University Health-Transplant Institute - Loma Linda

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2020-05-06
Est. Completion 2026-12
Phase NA

Sponsor

Loma Linda University

237 total trials

What the Registry Record Tells You About NCT04605679

The ClinicalTrials.gov registry entry for NCT04605679 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 586-participant average among 18 other Kidney Failure trials with a reported enrollment target (95% lower). The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Kidney Failure appearing as the primary indexed condition, and to 1 intervention - of which Kidney Transplantation is the first listed.

NCT04605679 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04605679 about?

NCT04605679 is a clinical study titled "Hepatitis C Virus (HCV) Positive Kidney Grafts in HCV Negative Recipients". To determine the efficacy and safety of transplanting HCV positive kidney allografts to HCV sero-negative patients who are on the waiting list.

What is the current status of trial NCT04605679?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 31 participants. The study started on 2020-05-06. Estimated completion is 2026-12.

What conditions does trial NCT04605679 study?

This clinical trial studies the following conditions: Kidney Failure.

What interventions are being tested in trial NCT04605679?

The interventions under investigation include: Kidney Transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT04605679?

This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04605679 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Kidney Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.